CSU, or chronic spontaneous urticaria, is a skin condition where itchy hives, swelling, or both appear repeatedly for six weeks or longer with no identifiable external trigger. Unlike a one-time allergic reaction, CSU is an ongoing disorder driven by the immune system mistakenly activating cells in the skin. It affects roughly 1 in 430 adults in the United States, with over 500,000 people living with the condition at any given time.
How CSU Differs From Regular Hives
Everyone gets hives at some point, usually from an allergic reaction, an infection, or a medication. Those episodes are classified as acute urticaria and resolve within six weeks. CSU starts the same way, with raised, itchy welts called wheals, but the episodes keep returning well past that six-week mark. The “spontaneous” in the name is important: unlike chronic inducible urticaria, where hives are triggered by something specific like cold air, pressure on the skin, or sunlight, CSU flares appear unpredictably without a clear external cause.
This unpredictability is one of the most frustrating aspects of the condition. You can’t reliably avoid flares the way you might avoid a known allergen, because the problem originates inside the immune system rather than from something in the environment.
What CSU Looks and Feels Like
The hallmark of CSU is wheals: raised, red or skin-colored patches that are intensely itchy. Individual wheals typically last anywhere from 30 minutes to 24 hours before fading, but new ones continue to appear. About 59% of people with CSU experience both wheals and angioedema, which is deeper swelling beneath the skin that commonly affects the eyelids, lips, hands, or feet. Another 36% have wheals alone, and a small group (around 5%) experience only the deeper swelling without surface hives.
When angioedema accompanies the hives, the wheals tend to last longer. The swelling itself can be uncomfortable or even painful, and when it affects the face, it’s often the symptom that prompts people to seek medical attention.
What Happens Inside the Skin
CSU is driven by mast cells, immune cells embedded in the skin that store histamine and other inflammatory chemicals. In a healthy immune response, mast cells release histamine when they detect a genuine threat like a parasite or allergen. In CSU, mast cells release their contents without a real threat, because the immune system is essentially attacking itself.
About 40% of people with CSU have autoantibodies circulating in their blood. These are immune proteins that mistakenly target either the antibody IgE (which sits on mast cell surfaces) or the receptor that IgE attaches to. When these autoantibodies bind to mast cells, they trigger degranulation, the process of dumping histamine into surrounding tissue, causing the itch, redness, and swelling of hives.
A second pathway involves what researchers call “autoallergy.” In these cases, the immune system produces IgE antibodies directed against the body’s own proteins, such as thyroid peroxidase (an enzyme in the thyroid gland). When those self-targeting antibodies encounter their target, they activate mast cells just as a real allergen would. This connection to thyroid proteins partly explains why thyroid conditions are more common in people with CSU.
Who Gets CSU
CSU is more than twice as common in women as in men. In the U.S., the prevalence among women is about 310 per 100,000 adults compared to 146 per 100,000 in men. The condition peaks between the ages of 40 and 59, though it can develop at any age. It is not contagious and does not spread through contact.
The Toll on Daily Life
Because CSU is rarely dangerous in the immediate sense, people sometimes underestimate how disruptive it is. The reality is that the condition significantly affects quality of life. In one study of CSU patients, nearly 80% had poor sleep quality. Nighttime itching fragments sleep, and the cumulative effect of chronic sleep disruption ripples into every part of daily functioning.
The psychological burden is substantial. In the same study, 58% of CSU patients had symptoms of depression, 59% had anxiety symptoms, and 43% reported significant stress. These mental health effects and poor sleep reinforce each other: patients with worse sleep had measurably higher depression, anxiety, and stress scores and reported greater overall impact on their quality of life. The unpredictability of flares, the visible skin changes, and the chronic itch create a cycle that’s difficult to break without treatment.
How CSU Is Treated
The first line of treatment is antihistamines, the same type of medication used for seasonal allergies but often at higher doses (up to four times the standard dose). For many people, this is enough to control or significantly reduce flares.
When antihistamines alone aren’t sufficient, the next step is a biologic medication called omalizumab, given as an injection every few weeks. It works by binding to IgE in the bloodstream, preventing IgE from attaching to mast cells and basophils. Over time, this reduces the number of IgE receptors on these cells, making them less reactive. In clinical trials, about 40% of patients achieved complete remission of symptoms within 12 weeks, and 50% to 70% saw a partial response. However, roughly 20% to 30% of patients don’t respond to this therapy and need alternative approaches.
Long-Term Outlook
CSU is classified as a self-limited condition, meaning it does eventually resolve for most people, though “eventually” can mean years. Within the first year, somewhere between 21% and 47% of patients go into remission. By year five, roughly 45% have seen their symptoms resolve. Looking further out, about 73% of patients are in remission by the 20-year mark. These numbers mean that while CSU is not permanent for most people, a significant portion live with it for many years, and a smaller group deals with it for decades.
Remission can also be unpredictable. Some people experience long symptom-free stretches followed by a return of hives, making it difficult to know whether the condition has truly resolved or is simply in a quiet phase. Treatment decisions often revolve around managing symptoms effectively during active periods while periodically testing whether the condition has run its course.